Fraser Gray, Hornet Therapeutics CEO
May 23, 2024 02:00 PM EDTUpdated 03:11 PM
Startups
R&D

UK biotech re­vives for­mer Ky­owa Kirin can­cer drug for Ep­stein-Barr-dri­ven dis­eases

Ayisha Sharma

News Reporter

Hor­net Ther­a­peu­tics is on a mis­sion to pre­vent and treat con­di­tions re­lat­ed to the Ep­stein-Barr virus (EBV) with the help of a drug can­di­date shelved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times